- Home
- CMPX vs VSTM Comparison
CMPX vs VSTM Comparison
Compare CMPX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- VSTM
- Stock Information
- Founded
- CMPX 2014
- VSTM 2010
- Country
- CMPX United States
- VSTM United States
- Employees
- CMPX N/A
- VSTM N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- VSTM Health Care
- Exchange
- CMPX Nasdaq
- VSTM Nasdaq
- Market Cap
- CMPX 206.3M
- VSTM 239.9M
- IPO Year
- CMPX N/A
- VSTM 2012
- Fundamental
- Price
- CMPX $1.42
- VSTM $4.26
- Analyst Decision
- CMPX Strong Buy
- VSTM Strong Buy
- Analyst Count
- CMPX 3
- VSTM 7
- Target Price
- CMPX $7.67
- VSTM $12.50
- AVG Volume (30 Days)
- CMPX 421.2K
- VSTM 996.6K
- Earning Date
- CMPX 11-12-2024
- VSTM 11-06-2024
- Dividend Yield
- CMPX N/A
- VSTM N/A
- EPS Growth
- CMPX N/A
- VSTM N/A
- EPS
- CMPX N/A
- VSTM N/A
- Revenue
- CMPX $850,000.00
- VSTM $10,000,000.00
- Revenue This Year
- CMPX N/A
- VSTM N/A
- Revenue Next Year
- CMPX $610.48
- VSTM $53.90
- P/E Ratio
- CMPX N/A
- VSTM N/A
- Revenue Growth
- CMPX N/A
- VSTM N/A
- 52 Week Low
- CMPX $0.77
- VSTM $2.10
- 52 Week High
- CMPX $2.34
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- CMPX 41.28
- VSTM 45.28
- Support Level
- CMPX $1.44
- VSTM $4.31
- Resistance Level
- CMPX $1.58
- VSTM $4.83
- Average True Range (ATR)
- CMPX 0.12
- VSTM 0.49
- MACD
- CMPX -0.01
- VSTM -0.14
- Stochastic Oscillator
- CMPX 11.63
- VSTM 4.02
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.